Current research [187] is also evaluating potential survival benefits in HCC patients resulting from the combination of Nivolumab with either a CCR2/5 inhibitor or an anti-IL8 antibody (BMS-986253), administered either pre- or post-surgery. This evidence concerns the gene CCR2 and hepatocellular carcinoma.